|

Brentuximab Vedotin Clinical Trials

14 actively recruiting trials across 6 locations

Also known as: ADC SGN-35, ADCETRIS Intravenous Infusion, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35 +5 more

Pipeline

Early 1: 1Phase 1: 1Phase 2: 8Phase 3: 2Phase 4: 1

Top Sponsors

  • Takeda2
  • Memorial Sloan Kettering Cancer Center2
  • M.D. Anderson Cancer Center2
  • Yale University1
  • University of Miami1

Indications

  • Cancer14
  • Hodgkin Lymphoma6
  • Mycosis Fungoides3
  • CD30-Positive Neoplastic Cells Present1
  • Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v81

Other3 trials

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Phase 4
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2

Birmingham, Alabama3 trials

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Children's Hospital of Alabama

Phase 3
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

University of Alabama

Early 1
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

University of Alabama at Birmingham

Phase 1

Stanford, California2 trials

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Stanford University - (Stanford Cancer Institute)

Phase 3
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Stanford University Medical Center

Phase 2

Miami, Florida2 trials

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

University of Miami

Phase 2
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

University of Miami

Phase 2

Houston, Texas2 trials

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

M D Anderson Cancer Center

Phase 2
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

MD Anderson Cancer Center

Phase 2

Sacramento, California1 trial

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 2

New Haven, Connecticut1 trial

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale Smilow Cancer Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.